Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Total Liabilities

Latest as of March 2026: CN¥1.30 Billion CNY ≈ $190.32 Million USD

Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has total liabilities worth CN¥1.30 Billion CNY (≈ $190.32 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Total Liabilities Trend (2019–2025)

This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See working capital position of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt to evaluate short-term liquidity relative to the company's equity base.

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Total Liabilities

The table below lists competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. ranked by their total liabilities.

Company	Country	Total Liabilities
Qiming Information Technology Co Ltd SHE:002232	China	CN¥465.75 Million
Vulcabras Azaleia S.A SA:VULC3	Brazil	R$1.52 Billion
Irish Continental Group PLC IR:IR5B	Ireland	€393.60 Million
Vaudoise Assurances Holding SA SW:VAHN	Switzerland	CHF6.34 Billion
Wuhan Zhongyuan Huadian Sci Tech SHE:300018	China	CN¥275.13 Million
Sparebanken Sor OL:SOR	Norway	Nkr158.47 Billion
Jiangsu Nanfang Bearing Co Ltd SHE:002553	China	CN¥303.04 Million
Zhang Xiaoquan Inc. SHE:301055	China	CN¥396.64 Million

Liability Composition Analysis (2019–2025)

This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301096 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.52	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)

The table below shows the annual total liabilities of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥1.20 Billion ≈ $175.20 Million	+4.86%
2024-12-31	CN¥1.14 Billion ≈ $167.08 Million	+15.92%
2023-12-31	CN¥984.97 Million ≈ $144.13 Million	+120.13%
2022-12-31	CN¥447.45 Million ≈ $65.48 Million	-26.30%
2021-12-31	CN¥607.10 Million ≈ $88.84 Million	+90.19%
2020-12-31	CN¥319.20 Million ≈ $46.71 Million	+219.55%
2019-12-31	CN¥99.89 Million ≈ $14.62 Million	--

About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

SHE:301096 China Drug Manufacturers - General

Market Cap

$890.60 Million

CN¥6.09 Billion CNY

Market Cap Rank

#9590 Global

#2519 in China

Share Price

CN¥55.72

Change (1 day)

+1.05%

52-Week Range

CN¥43.14 - CN¥68.99

All Time High

CN¥98.58